Skip to main content
Clinical Trials/JPRN-jRCT2080223746
JPRN-jRCT2080223746
Completed
Phase 2

The clinical study to evaluate the efficacy, safety, and pharmacokinetics of MD-0901 in pediatric patients with mildly to moderately active ulcerative colitis.

MOCHIDA PHARMACEUTICAL CO., LTD0 sites26 target enrollmentDecember 8, 2017

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Mildly to moderately active ulcerative colitis
Sponsor
MOCHIDA PHARMACEUTICAL CO., LTD
Enrollment
26
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 8, 2017
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
MOCHIDA PHARMACEUTICAL CO., LTD

Eligibility Criteria

Inclusion Criteria

  • (1\)Subjects who are diagnosed as ulcerative colitis
  • (2\)Subjects who are total score of 3\-8 on the Ulcerative Colitis Disease Activity Index (UC\-DAI) with a sigmoidoscopy score of 1 or higher, a rectal bleeding score of 1 or higher, and a Physician's Global Assessment (PGA) score of 2 or less at the baseline
  • (3\)Body weight 18\-90 kg at the baseline

Exclusion Criteria

  • (1\)Subjects with a history of colectomy (except appendectomy)
  • (2\)Subjects with moderate/severe renal or liver impairment
  • (3\)Subjects with serious blood disorder, respiratory disorder, digestive disorder, cardiovascular disorder, psychiatric disorder, abnormal electrolyte metabolism disorder or hypersensitivity as complication
  • (4\)Subjects with malignant tumor as complication

Outcomes

Primary Outcomes

Not specified

Similar Trials